Evidence map›Paper›PMID 31345711›Full record

ArticleThe Lancet. Infectious diseases2019

Accelerated evolution and spread of multidrug-resistant Plasmodium falciparum takes down the latest first-line antimalarial drug in southeast Asia.

Didier Ménard, David A Fidock

Abstract readComment
In one paragraph

Article in The Lancet. Infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed.

  1. Changing genetic profiles ofAntimicrobial agents and chemotherapy · 2026
    Article
  2. Article
  3. Characterization of the malaria parasiteMicrobiology spectrum · 2025
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors.

Didier MénardBiology of Host-Parasite Interactions Unit, Malaria Genetics and Resistance Group, Institut Pasteur, INSERM U1201, CNRS ERL9195, Paris, France. Electronic address: dmenard@pasteur.fr.
David A FidockDepartment of Microbiology and Immunology, and Division of Infectious Diseases, Department of Medicine, Columbia University Irving Medical Center, New York, NY, USA.

Funding

Leveraging PfCRT Structure to Discern Function and Predict Emergence of Drug-Resistant MalariaR01AI147628 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock, Filippo Mancia · 2019 to 2026
$5.1M
Defining the Role of PfCRT and PfMDR1 as Pleiotropic Mediators of Plasmodium falciparum Multidrug ResistanceR37AI050234 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2018 to 2026
$4.4M
Defining P. falciparum resistance to artemisinin-based combination therapiesR01AI109023 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI FIDOCK, DAVID A · 2014 to 2025
$4.4M
Elucidating the molecular basis of piperaquine resistance in Plasmodium falciparumR01AI124678 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI David A Fidock · 2016 to 2026
$4.3M
NIAID NIH HHS R01 AI109023NIAID NIH HHS R01 AI124678NIAID NIH HHS R37 AI050234
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AntimalarialsMalariaMalaria, FalciparumAsia, SoutheasternGenomicsHumansPlasmodium falciparumAntimalarials

Identifiers

PMID31345711
PMCPMC6754981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.